How Will Shifts in GLP-1 RA Pricing & Coverage Impact Clinical Practice?

A recent analysis in JAMA Network Open suggests that Most Favored Nation pricing and expanded coverage for GLP-1 receptor agonists will increase drug spending—but how will this impact physicians and their patients? **Elizabeth Kazarian, MD,** weighs in. Read the full Q&A here. ### Contributor **Elizabeth Kazarian, MD** Primary Care Physician & Obesity Specialist PMA Health * * * Let us know what you thought of this week’s episode on X: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the podcast? Email us at [editorial@physweekly.com.](mailto:editorial@physweekly.com) *Thanks for listening.* *Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of* Physician’s Weekly*, their employees, and affiliates.*